Vaxcyte, Inc. (PCVX)
Vaxcyte is developing pneumococcal vaccines for adults and children, made with its XpressCF protein production platform. It last closed at $59.46 on Nov 17, down 3.49% on the day. The average 12-month price target from 4 analysts is $124.25 (+109.0% from the last close), with a high of $130.00 and a low of $120.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in PCVX, 0% of them bullish and 100% bearish. In the past 30 days there were 4 dark pool prints totaling $2.9M, the largest $910K.
Key Stats
Last 12 monthsNot reported for this period.
From PCVX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on PCVX in the past 90 days. The average target is $124.25, with a high of $130.00 and a low of $120.00, compared with the last close of $59.46.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | Cantor Fitzgerald | Reiterated | Buy | $120 |
| Oct 5 | Needham | Maintained | Buy | $122 |
| Oct 5 | Guggenheim | Maintained | Buy | $125 |
| Sep 28 | B of A Securities | Maintained | Buy | $130 |
Technical Analysis
The stock is 6% below its 20 day and 5% below its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 26) at $59.19, and the nearest resistance the swing high (Jun 30) at $59.50.
| RSI (14) | 43.09 | Middle of its range | Neutral |
| MACD | 0.07 | Below its signal line | Bearish |
| Stochastic | 22.4 | Middle of its range | Neutral |
| ADX (14) | 23.7 | Weak trend | |
| Williams %R | -96.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -100.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −2.2% | Change over 10 sessions | Bearish |
| ATR (14) | $3.32 | Typical daily range, 5.6% of price |
| RSI (14) | 50.73 | Middle of its range | Neutral |
| MACD | 2.11 | Below its signal line | Bearish |
| Stochastic | 21.6 | Middle of its range | Neutral |
| ADX (14) | 29.8 | Trending up | |
| Williams %R | -87.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | 3.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −0.0% | Change over 10 sessions | Bearish |
| ATR (14) | $6.68 | Typical daily range, 11.2% of price |
What happened before
See how PCVX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PCVX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in PCVX in the last 90 days.
Dark Pool
30DPCVX Institutional Ownership
Full report →- ▲196 buying vs 143 selling
- ▲Held by funds +1.5 pts
- ▲Funds holding +22
- ▼Superinvestors: 1 added, 3 cut
- ▲Put/call 2.09 to 1.63
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 357 | 335 | +6.6% |
| In funds' top 10 | 10 | 14 | −28.6% |
| Held by funds | 107.4% | 105.9% | +1.5 pts |
| New / increased | 65 / 131 | 47 / 132 | +9.5% |
| Reduced / sold out | 101 / 42 | 100 / 51 | −5.3% |
| Put/call ratio | 1.63 | 2.09 | −22.2% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCVX is in one of them and how their past PCVX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PCVX in an article yet. Here's the latest on the wider market.
PCVX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jul 16, 2026 | Sep 4, 2026 | 50 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | May 13, 2026 | Jun 8, 2026 | 26 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | May 12, 2026 | Jun 8, 2026 | 27 d |
| Sean DuffyExecutive branch | Sell | $1K – $15K | Feb 11, 2025 | May 14, 2025 | 92 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Apr 28, 2025 | May 7, 2025 | 9 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Vaxcyte
Vaxcyte is a biotechnology company based in San Carlos, California, that is developing vaccines to protect against bacterial diseases. Its main focus is pneumococcal vaccines, which guard against infections caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis. The company uses XpressCF, a protein production platform that does not rely on living cells, to make these complex vaccines. Its candidates are still in clinical trials for adults and infants, so they are not yet sold.
- Headquarters
- San Carlos, CA







